Anti-CD40 ligand antibody permits regeneration through peripheral nerve allografts in a nonhuman primate model

Plastic and Reconstructive Surgery

Volumn 114, Issue 7, 2004, Pages 1802-1814

  Brenner, Michael J ^a   Jensen, John N ^a   Lowe III, James B ^a   Myckatyn, Terence M ^a   Fox, Ida K ^a   Hunter, Daniel A ^a   Mohanakumar, T ^a   Mackinnon, Susan E ^a,b  

^a Campus Box 8238 ^*

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131;

ADOLESCENT; ALLOGRAFT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; EXPERIMENTAL MODEL; GRAFT REJECTION; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; ISOGRAFT; MACACA; MIXED LYMPHOCYTE REACTION; MONOTHERAPY; NERVE GRAFT; NERVE REGENERATION; NERVE TRANSPLANTATION; NONHUMAN; PERIPHERAL NERVE; PERIPHERAL NERVE ALLOGRAFT; PRIORITY JOURNAL; SKIN GRAFT; ULNAR NERVE;

EID: 14944349757     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PRS.0000143575.88064.D0     Document Type: Article

References (24)

1. Mackinnon, S. E., Doolabh, V. B., Novak, C. B., and Trulock, E. P. Clinical outcome following nerve allograft transplantation. Plast. Reconstr. Surg. 107: 1419, 2001.
2. Atchabahian, A., Mackinnon, S. E., and Hunter, D. A. Cold preservation of nerve grafts decreases expression of ICAM-1 and class II MHC antigens. J. Reconstr. Microsurg. 15: 307, 1999.
3. De Martini, I, Bianchini, D., Schenone, A., et al. Class II antigen expression on human cultured Schwann cells from patients with Charcot-Marie-Tooth disease. Neurosci. Lett. 100: 331, 1989.
4. Maehlen, J., Schroder, H. D., Klareskog, L., Olsson, T., and Kristensson, K. Axotomy induces MHC class I antigen expression on rat nerve cells. Neurosci. Lett. 92: 8, 1988.
5. Yu, L. T., Rostami, A., Silvers, W. K., Larossa, D., and Hickey, W. F. Expression of major histocompatibility complex antigens on inflammatory peripheral nerve lesions. J. Neuroimmunol. 30: 121, 1990.
6. Lassner, F., Schaller, E., Steinhoff, G., Wonigeit, K., Walter, G. F., and Berger, A. Cellular mechanisms of rejection and regeneration in peripheral nerve allografts. Transplantation 48: 386, 1989.
7. Mackinnon, S., Hudson, A., Falk, R., Bilbao, J., Kline, D., and Hunter, D. Nerve allograft response: a quantitative immunological study. Neurosurgery 10: 61, 1982.
8. Midha, R., Evans, P.J., Mackinnon, S. E., and Wade, J. A. Temporary immunosuppression for peripheral nerve allografts. Transplant. Proc. 25: 532, 1993.
9. Midha, R., Mackinnon, S. E., and Becker, L. E. The fate of Schwann cells in peripheral nerve allografts. J. Neuropathol. Exp. Neurol. 53: 316, 1994.
10. Becker, D. B., Jensen, J. N., Myckatyn, T. M., Doolabh, V. B., Hunter, D. A., and Mackinnon, S. E. Effects of FKBP-12 ligands following tibial nerve injury in rats. J. Reconstr. Microsurg. 16: 613, 2000.
11. Doolabh, V. B., and Mackinnon, S. E. FK506 accelerates functional recovery following nerve grafting in a rat model Plast. Reconstr. Surg. 103: 1928, 1999.
12. Fansa, H., Keilhoff, G., Altmann, S., Plogmeier, K., Wolf, G., and Schneider, W. The effect of the immunosuppressant FK506 on peripheral nerve regeneration following nerve grafting. J. Hand Surg. (Br.) 24: 38, 1999.
13. Gold, B. G., Katoh, K., and Storm-Dickerson, T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J. Neurosci. 15: 7509, 1995.
14. Brenner, M.J., Tung, T. H., Jensen, J. N., and Mackinnon, S. E. The spectrum of complications of immunosuppression: is the time right for hand transplantation? J. Bone Joint Surg. (Am.) 84: 1861, 2002.
15. Midha, R., Mackinnon, S. E., Evans, P. J., et al. Comparison of regeneration across nerve allografts with temporary or continuous cyclosporin A immunosuppression. J. Neurosurg. 78: 90, 1993.
16. Kirk, A. D., Burkly, L. C., Batty, D. S., et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5: 686, 1999.
17. Kirk, A. D., Blair, P. J., Tadaki, D. K., Xu, H., and Harlan, D. M. The role of CD154 in organ transplant rejection and acceptance. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356: 691, 2001.
18. Larsen, C. P., Elwood, E. T., Alexander, D. Z., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381: 434, 1996.
19. Buhler, L., Alwayn, I. P., Appel, J. Z., III, Robson, S. C., and Cooper, D. K. Anti-CD154 monoclonal antibody and thromboembolism. Transplantation 71: 491, 2001.
20. Kawai, T., Andrews, D., Colvin, R. B., Sachs, D. H., and Cosimi, A. B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 6: 114, 2000.
21. Jensen J. N., Tung T. H., Mackinnon, S. E., Brenner, M.J., and Hunter, D. A. Use of anti-CD40 ligand monoclonal antibody as anti-rejection therapy in a murine peripheral nerve allograft model. Microsurgery 24: 309, 2004.
22. Kirk, A. D., Harlan, D. M., Armstrong, N. N., et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. U. S. A. 94: 8789, 1997.
23. Kirk, A. D. Transplantation tolerance: a look at the nonhuman primate literature in the light of modern tolerance theories. Crit Rev. Immunol. 19: 349, 1999.
24. Elwood, E. T., Larsen, C. P., Cho, H. R., et al. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation 65: 1422, 1998.